Philadelphia Phillies Trade LHP Cole Irvin To Oakland Athletics

PHILADELPHIA (CBS/AP) -- A busy week continued for the Philadelphia Phillies on Saturday. The Phillies traded left-handed Cole Irvin to the Oakland Athletics for cash.

Irvin, who turns 27 on Sunday, was 0-1 with a 17.18 ERA in three relief appearances last season. He gave up seven runs and 11 hits in 3 2/3 innings.

Irvin made his big league debut with the Phillies in 2019, going 2-1 with a 5.83 ERA. He pitched 16 games, including three starts.

A fifth-round draft pick in 2016, he was 34-15 with a 3.07 ERA over four seasons in the minors, mostly as a starter.

Earlier Saturday, the Phillies and shortstop Didi Gregorius have agreed on a two-year, $28 million contract, according to a person familiar with the deal. The person spoke to The Associated Press on condition of anonymity Saturday because the deal is pending Gregorius passing a physical.

Gregorius, who turns 31 next month, batted .284 with 10 homers, 40 RBIs and an .827 OPS in 60 games in his first season with the Phillies.

Gregorius hit .274 and averaged 20 homers and 75 RBIs over four seasons with the Yankees between 2015-18. He hit 16 homers and drove in 61 runs in 82 games in 2019 after Tommy John surgery on Oct. 17, 2018, to repair a torn elbow ligament.

The Phillies signed two-time All-Star catcher J.T. Realmuto to a five-year, $115.5 million deal earlier in the week.

Philadelphia hasn't reached the postseason since 2011, the last year it had a winning record. The Phillies finished 28-32 in a pandemic-shortened 2020 season, missing a wild-card berth by one game in the expanded playoff format.

(© Copyright 2021 CBS Broadcasting Inc. All Rights Reserved. The Associated Press contributed to this report.)

MORE ON CBSPHILLY.COM

Winter Storm Watch In Place As Region Braces For Possibility Of Several Inches Of Snow

Playland's Castaway Cove Damaged After 4-Alarm Blaze Erupts On Ocean City Boardwalk

Philadelphia Health Commissioner Addresses Calls For Resignation In Wake Of Philly Fighting COVID Controversy

Read more
f

We and our partners use cookies to understand how you use our site, improve your experience and serve you personalized content and advertising. Read about how we use cookies in our cookie policy and how you can control them by clicking Manage Settings. By continuing to use this site, you accept these cookies.